Delivering on the promise of RNA therapeutics

SiSaf is an RNA delivery and therapeutics company.

Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.

We are advancing a first-in-class pipeline of RNA therapeutics for rare and currently incurable autosomal dominant diseases of the bone and eye, alongside partnering with others to maximise the value Bio-Courier technology brings to RNA therapeutics and vaccines.

Our Science

Our silicon-stabilized hybrid lipid nanoparticles (sshLNPTM) improve the stability, safety, and transfection efficiency of RNA.

Learn more

Pipeline

We are developing a growing pipeline of RNA therapeutics for rare diseases

Learn more

Partnering

We are partnering with leaders in the field of RNA therapeutics

Learn more

News

SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation

More

RNA Delivery and Therapeutics Company SiSaf Announces Autumn Conference Schedule

More

SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

More

RNA Therapeutics Company SiSaf to Present at Upcoming Conferences

More

SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical Advisor

More

SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease

More

SiSaf Ltd utilizes Intoolab’s Tzager AI Platform

More

SiSaf Ltd Announces US$13.2 Million Series B Financing

More

Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium

More

SiSaf announces licencing agreement to develop gene therapy for rare bone disease

More

SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research

More

SiSaf Establishes Strategic Partnership with Avellino Labs

More